INSM logo

INSM Insmed Incorporated

NASDAQ Global Select · Biotechnology · Healthcare

$141.33
-3.13 (-2.17%)

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its developme…

Market Cap: $31.00Bwww.insmed.com

Price

No data yet.

Social Signal Score

59
5d
60
6 mentions
—
30d
58
18 mentions
—
60d
58
26 mentions
—
90d
58
40 mentions
—
news: 30 · rss: 9 · marketaux: 1

Analyst Ratings

36 analysts
Buyconsensus
Strong Buy 0Buy 33Hold 2Sell 1Strong Sell 0
Avg price target$191.06+35.2%
Low $154Median $193.5High $235
Current Consensus

Revenue

$524.43M
$0.00$174.81M$349.62M$524.43M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-5.85
$-6.58–$-5.44
12 analysts
FY2026
$-1.62
$-2.15–$-1.38
16 analysts
FY2027
$0.68
$-0.93–$2.30
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
William H. Lewis
Sector
Healthcare
Industry
Biotechnology
Employees
1,664
Beta
0.81
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
9.20
www.insmed.com